An audit of compliance with NICE guidelines for use of rituximab as first line maintenance treatment of follicular non-Hodgkin's lymphoma, in line with East Midlands Guidelines

被引：0
|
作者：
Attwood, C. [1 ]
Boden, A. [1 ]
Fox, C. [1 ]
Richardson, F. [1 ]
McMillan, A. [1 ]
Haynes, A. [1 ]
机构：
[1] Nottingham Univ Hosp NHS Trust, Dept Haematol, Nottingham, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 161卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
139
引用
收藏
页码：55 / 56
页数：2
相关论文
共 50 条
  • [41] Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial
    Hainsworth, JD
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 25 - 29
  • [42] Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma
    Lopez-Guillermo, Armando
    Caballero, Dolores
    Canales, Miguel
    Provencio, Mariano
    Rueda, Antonio
    Salar, Antonio
    LEUKEMIA & LYMPHOMA, 2011, 52 : 1 - 14
  • [43] EFFICACY AND TOXICITY OF IMMUNO CHEMOTHERAPY AND MAINTENANCE WITH RITUXIMAB IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA. EXPERIENCE OF A CENTRE
    Barranco Pilar, Martinez
    Francisco Javier, Penalver Parraga
    Blanco Lucia, Villalon
    Juaristi Karmele, Arribalzaga
    Maria Jose, Garcia Bueno
    Andres Pilar, Ricard
    HAEMATOLOGICA, 2016, 101 : 365 - 366
  • [44] First-line treatment with Bendamustine plus Rituximab for patients with indolent non-Hodgkin's lymphoma or Mantle cell lymphoma: Real-world experience.
    Kotchetkov, Rouslan
    Susman, David
    Gerard, Lauren
    DiMaria, Erica
    Nay, Derek Wayne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with 131I-Rituximab: The INITIAL Study
    McQuillan, Andrew D.
    Macdonald, William B. G.
    Leahy, Michael F.
    Turner, J. Harvey
    BLOOD, 2011, 118 (21) : 1589 - 1589
  • [46] Fludarabine, cyclophosphamide and rituximab up to four courses as first line treatment for indolent non-hodgkin lymphomas
    Falantes, J. F.
    Ríos Herranz, E.
    Marin Niebla, A.
    Martino Galiana, M. L.
    Parody, R.
    Blas Orlando, J. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 403 - 403
  • [47] The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma
    Barrington, Sally F.
    Trotman, Judith
    LANCET HAEMATOLOGY, 2021, 8 (01): : E80 - E93
  • [48] A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
    R Marcus
    R Aultman
    F Jost
    British Journal of Cancer, 2010, 102 : 19 - 22
  • [49] A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment
    Prodanovic, Edward
    Korman, Neil
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB119 - AB119
  • [50] Use of Rituximab in Combination with Conventional Chemotherapy for the Treatment of Non-Hodgkin's Lymphoma of the Head and Neck
    Manolopoulos, Leonidas
    Gomatos, Ilias P.
    Leandros, Emmanuel
    Alevizos, Leonidas
    Georgiou, Natasa
    Giotakis, John
    Ferekidis, Eleutherios
    IN VIVO, 2009, 23 (03): : 475 - 478
12345